Life Sciences News | BioTuesdays by Kilmer Lucas IR

Executive Moves

Laurie Keating joins Kalaris BOD

Kalaris Therapeutics (NASDAQ: KLRS) has announced the appointment of Laurie Keating to its board of directors (BOD), effective August 1, 2026, and the departure of Morana Jovan-Embiricos from the board. Ms. Keating...

July 7, 2026

Executive Moves

Longeveron appoints Marie Washburn as CFO

Longeveron (NASDAQ: LGVN) has announced the appointment of Marie Washburn as senior vice president and chief financial officer (CFO), effective July 13, 2026. Ms. Washburn has served as Longeveron’s vice president...

July 7, 2026

Developments

FDA accepts Organogenesis’ ReNu BLA for knee OA

Organogenesis Holdings (NASDAQ: ORGO) has announced that the FDA has accepted for review its Biologics License Application (BLA) for ReNu, a cryopreserved, amniotic suspension allograft developed for the treatment of...

July 7, 2026

Markets

Rodman & Renshaw starts Atossa at buy; PT $12

Rodman & Renshaw initiated coverage of Atossa Therapeutics (NASDAQ: ATOS) with a “buy” rating and price target of $12.00. The stock closed at $2.28 on July 6. Atossa, a clinical-stage biopharmaceutical company...

July 7, 2026

Markets

Paradigm Capital names Perimeter and maintains Profound as healthcare Top Picks

Paradigm Capital has named Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) as a new Top Pick with a “speculative buy” rating and C$0.95 price target. The stock closed at C$0.275 on July 3. Commenting on the FDA’s...

July 6, 2026

Developments

Alligator highlights first patient dosed in trial of mitazalimab in breast cancer

Alligator Bioscience (STO: ATORX) has announced that the first patient has been dosed in an investigator-led trial evaluating the intratumoral administration of mitazalimab, the company’s lead CD40 agonist, in patients...

July 2, 2026

Executive Moves

Inogen appoints Andy Reding as COO

Inogen (NASDAQ: INGN) has announced the appointment of Andy Reding to the newly created role of chief operating officer (COO), effective Monday, July 6, 2026. Mr. Reding will be responsible for driving revenue and...

July 2, 2026

Developments

FDA grants Sonoma 510(k) clearance for Microdacyn Wound Irrigation Solution

Sonoma Pharmaceuticals (NASDAQ: SNOA) has received a new 510(k) clearance from the FDA for its Microdacyn Wound Irrigation Solution, including expanded claims, clearance for multiple use, and additional packaging...

June 30, 2026

Executive Moves

Dr. Iain Dukes joins Dogwood as chair of SAB

Dogwood Therapeutics (NASDAQ: DWTX) has announced the appointment of Iain Dukes, PhD, as chair of the company’s scientific advisory board (SAB). Dr. Dukes is a veteran biopharma industry executive and partner with...

June 30, 2026

Developments

Pasithea reports positive interim Phase 1 cancer study data

Pasithea Therapeutics (NASDAQ: KTTA) has announced updated interim safety and clinical activity data from its ongoing first-in-human trial of PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a...

June 30, 2026

Executive Moves

Candel appoints Mark Sims as CCO

Candel Therapeutics (NASDAQ: CADL) has announced the appointment of Mark Sims as its chief commercial officer (CCO), effective July 6, 2026. Mr. Sims will lead Candel’s commercial strategy and launch readiness for...

June 25, 2026

Developments

Sunshine receives Canadian regulatory approval for generic Anastrozole tablets

Sunshine Biopharma (NASDAQ: SBFM) has announced the approval of its generic Anastrozole tablets of 1mg for the treatment of postmenopausal women with hormone receptor-positive breast cancer in the Canadian market...

June 25, 2026

Subscribe